Shots:

• In early H2’19- STADA is launching its biosimilar teriparatide- Movymia as a cost-effective with the patent expiration of the reference product Forsteo leading to expansion of STADA’s biosimilar portfolio in the EU
• Forsteo is a form of parathyroid hormone used to make the bones stronger- and to reduce the risk of fractures by stimulating bone formation and has produced sales of EUR 250M in a year in the EU
• Movymia is a re-fillable multidose injection device called Movymia Pen and the treatment of osteoporosis is only active ingredient approved for osteoanabolic therapy

Click here to read full press release/ article | Ref: STADA | Image: Twitter